Almost everything else on a health review has a symptom attached to it. Thyroid trouble makes you cold and slow. Insulin resistance flattens your afternoon. Poor sleep shows up in how you think by Thursday. You notice, and eventually you go looking.

Arterial disease does not work that way. Plaque builds inside the artery wall over decades, and a vessel can narrow a long way before blood flow is affected enough to produce anything you would notice. The European Atherosclerosis Society consensus, drawing on more than 200 prospective cohort studies, genetic studies and randomised trials covering over two million people, describes the relationship as dose-dependent, and reports that the effect appears to grow with how long the artery has been exposed.¹

Which means there is no moment at which your body tells you to check. The only signal this one gives is the one you go and measure.

Two people can have an identical LDL cholesterol result and be carrying very different numbers of particles, and therefore very different risk. That is the single most useful thing to understand here, and it follows from how the measurement works.

Cholesterol does not travel loose in blood. It is carried inside particles, and every particle capable of getting into an artery wall carries exactly one copy of a protein called apolipoprotein B. One particle, one ApoB. So measuring ApoB counts the vehicles. Measuring LDL cholesterol weighs the cargo they happen to be carrying.²

When particles are small and under-filled, it takes more of them to carry the same amount of cholesterol. The cholesterol number comes back looking the same. The traffic on the road has roughly doubled. It is the number of particles arriving at the artery wall that determines how many get stuck there, which is why the count and the content can tell you different things about the same blood. The distinction between a result that is inside the reference range and one that is genuinely reassuring shows up here more sharply than almost anywhere else on a panel.

The situation worth knowing about is the one where a person is reassured by a result that is not telling the whole story. It has a name in the literature: discordance.

In 13,015 statin-treated adults in Copenhagen followed for a median of eight years, those whose ApoB sat above the median while their LDL cholesterol sat below it had a higher rate of heart attack and of death from any cause than those with both below. The reverse combination, high LDL cholesterol with low ApoB, carried no increase at all.³

The largest analysis to date pooled 389,529 adults from the UK Biobank who were not on lipid-lowering therapy with 40,430 patients on statins who already had established disease. Assessed one at a time, ApoB, non-HDL cholesterol and triglycerides were each associated with heart attack. Assessed together, only ApoB remained.⁴ An earlier meta-analysis of twelve studies covering 233,455 people and 22,950 events had ranked them the same way, with ApoB the strongest of the three markers and LDL cholesterol the weakest.⁵

None of this makes the standard panel wrong. It makes it incomplete in a specific and predictable set of people.

The people most likely to be reassured wrongly are the ones whose problem is metabolic rather than lipid. Triglycerides drifting up, HDL cholesterol drifting down, a waist that has quietly changed shape, and an LDL cholesterol that reads perfectly acceptable.

In 422 apparently healthy adults, the group with a raised ApoB despite a low LDL cholesterol had significantly higher triglycerides and a higher triglyceride-to-HDL ratio than the group whose numbers agreed. That ratio identified the high-risk discordant group well, with an area under the curve of 0.85, which in plain terms means it was right far more often than chance.⁷

The useful part of that finding is how ordinary it is. Triglycerides and HDL are already on every standard panel. Read as a ratio rather than as two separate lines, they are a reasonable first clue that a reassuring LDL cholesterol may be hiding a high particle count. It is the same metabolic pattern that sits underneath the mid-afternoon energy collapse and behind insulin resistance in women over 40, which is why cardiovascular risk and metabolic health are hard to look at separately.

At 50, the number on today’s test matters less than the number you have been carrying since 30. The consensus evidence describes an effect that appears to grow with the duration of exposure as well as its size.¹ A moderately raised particle count carried quietly through two decades can add up to more arterial exposure than a higher one found and dealt with at 55.

That reframes what an early measurement is for. It is not there to tell you whether something is wrong today. It is there to tell you what you have been accumulating, while there is still a long time in which changing it counts for something.

The same logic applies to checking whether anything is working. Across seven placebo-controlled statin trials, the size of the risk reduction tracked the fall in ApoB more closely than the fall in either LDL cholesterol or non-HDL cholesterol.⁸ If the particle count is what the artery responds to, it is also the sensible thing to re-measure.

Some people carry an inherited particle that raises their risk regardless of how good the rest of the panel looks, and a standard panel does not look for it.

Lipoprotein(a) is an LDL-like particle with an extra protein attached. Its level is set largely by genetics, so it stays broadly stable through life and responds very little to diet or to statins. The 2022 European Atherosclerosis Society consensus concluded that the association with cardiovascular outcomes is causal and continuous across different ethnic groups, that a raised level is a risk factor even when LDL cholesterol is very low, and that it should be measured at least once in every adult.⁹

There is no approved therapy yet shown to reduce cardiovascular events by lowering Lipoprotein(a) specifically. What a high result changes is the seriousness with which everything else is managed, and how early. Because the level barely moves, one measurement in a lifetime is generally enough.

ApoB is better than LDL cholesterol. It is not the whole answer, and it would be dishonest to present it as one.

In 17,532 adults with no cardiovascular disease at baseline, pooled from three large American cohorts and followed for a median of almost 19 years, remnant cholesterol predicted events after adjusting for both LDL cholesterol and ApoB. The authors described the finding as surprising and said the mechanism needs further work.¹⁰ Something is being carried by those particles that a count alone does not capture.

The comparison literature is also messier than a summary makes it sound. A 2025 review points out that studies define discordance in three different ways, that results from the different approaches cannot be directly compared, and that findings have been inconsistent and at times conflicting. What survives that scrutiny is the plainest version: in people not on lipid-lowering medication, a raised LDL cholesterol, non-HDL cholesterol or ApoB each signals increased risk, and in people already on treatment, ApoB and non-HDL cholesterol give the better read on what risk remains.¹¹

There is a practical gap too. Guidelines have not settled on consistent ApoB targets the way they have for LDL cholesterol, and a 2024 review in Circulation set out to propose evidence-guided thresholds precisely because that absence has slowed the marker’s adoption.¹² The number is currently read against a person’s overall risk rather than against one agreed line.